



MO HealthNet Pharmacy SmartPA – Pharmacy Prior Authorization

Joshua Moore, PharmD Director of Pharmacy February 13, 2020

MHD Pharmacy Goal

Enable and support the best treatment for MO HealthNet Participants in a fiscally responsible and sustainable way

Pharmacy Policy Management Process

What does evidence say is best practice? What is everyone else doing? What is the provider experience? What does our data show? What does the data mean? What is the appropriate level of 3rd Party influence?

Drug Prior Authorization Process

Pipeline review

• MHD reviews the pharmacy pipeline for new agents which are expected to be approved in the next 12 months

New medication is approved by FDA

• This includes new molecule or dosage form

Medication reported to First Databank

• Within 1 week the medication is placed on new drug review

MHD meets with team of clinicians to develop initial criteria

 Initial criteria is used until the medication can be reviewed by advisory boards

Drug Prior Authorization Process

MHD creates proposal documents for advisory committee

Rare Disease Medications

 If medication impacts <200,000 participants will be reviewed by Rare Disease Advisory Committee

Prior Authorization Committee

• Public meeting to review PA criteria

Drug Utilization Review Board

• Public meeting to review PA criteria and Drug Utilization information

MHD implements criteria in the SmartPA System

MO HealthNet Criteria

Preferred Drug List (PDL) Edits

Contain preferred and non-preferred agents and may have clinical criteria

Clinical Edits

• Contain clinical criteria, dosage limitations, and other criteria as needed

Fiscal Edits


• Criteria is limited to dose unit optimization and refill too soon limits

MO HealthNet Criteria

- Posted on MO HealthNet's website
- Reviewed by DPAC and DUR Committee on annual basis at the quarterly meetings
- Also may be reviewed by Rare Disease Advisory Committee if disease impacts <200,000 persons in United States

SmartPA Rules Engine

- 6 million claims evaluated by SmartPA
- 587k claims denied at Point of Sale (10%)
- 85k claims result in call to Pharmacy HD (14.5% of denied claims)
- 18k prior authorization requests denied (21% of requests, 0.3% of total claims submitted)
- Statistics for SFY19



Benefits of SmartPA

Transparent automated application of uniform standards Real time authorization

• Call center is able to enter overrides in real time

Allows for high PDL Compliance

• 96% Compliant to PDL

Allows for clinical decisions to be embedded in the Point of Sale Transaction

Typically review up to 3 years of patient specific history when making decisions

Interventions are able to shift utilization

Coming Fall 2020 – diagnosis code on pharmacy claims

Opioids & Benzodiazepines

Opioid utilization decreased by over 50% in 2 years

- 508 million MME in calendar year 2017
- 252 million MME in calendar year 2019

Benzodiazepine utilization decreased by 19% after edit implemented

- 1.2 million units dispensed in July 2019
- Implemented mid-August 2019
- 1.0 million units dispensed in October 2019

Questions?